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Background: Rabies, a zoonosis found throughout the globe, is caused by a virus of the Lyssavirus genus. The
disease is transmitted to humans through the inoculation of the virus present in the saliva of infected mammals.
Since its prognosis is usually fatal for humans, nationwide public campaigns to vaccinate dogs and cats against
rabies aim to break the epidemiological link between the virus and its reservoirs in Brazil.
Findings: During 12 months we evaluated the active immunity of dogs first vaccinated (booster shot at 30 days
after first vaccination) against rabies using the Fuenzalida-Palácios modified vaccine in the urban area of Botucatu
city, São Pauto state, Brazil. Of the analyzed dogs, 54.7% maintained protective titers (≥0.5 IU/mL) for 360 days after
the first vaccination whereas 51.5% during all the study period.
Conclusions: The present results suggest a new vaccination schedule for dogs that have never been vaccinated. In
addition to the first dose of vaccine, two others are recommended: the second at 30 days after the first and the
third dose at 180 days after the first for the maintenance of protective titers during 12 months.
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Half of the world population (3.5 billion people) lives in
areas where there is an increase of dogs, cats and ro-
dents, and therefore the frequency of zoonoses transmit-
ted by these animals is also augmented [1]. Globally,
rabies provokes 40,000 to 70,000 deaths per year and ap-
proximately 15 million people receive post-exposure ra-
bies treatment [2-4]. This means that rabies kills one
person every minute worldwide [5]. Rabid dogs are re-
sponsible for 99% of these deaths and 92% of post-
exposure treatments [1]. In Brazil, 140 people died due to
rabies between 2001 and 2010, in 40% of these cases the
disease was contracted from dogs, in 1.43% from cats, in
53.57% from bats and in 5% of the cases from other ani-
mals [6]. The protection of humans against urban rabies is
achieved mainly by prophylactic measures applied to dogs
and cats, which include vaccines that induce minimum
antibody titers (≥0.5 IU/L) [7]. In Brazil, vaccination* Correspondence: jrmodolo@fmvz.unesp.br
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in mass vaccination campaigns, numerous animals do not
achieve protective antibody titers after vaccinated with
Fuenzalida-Palácios modified vaccine (Institute of Tech-
nology of Paraná, TECPAR®) [8-10]. The present study
aimed to evaluate during 12 months the kinetics of anti-
bodies in dogs that were first vaccinated against rabies.
The study was conducted in 2009 during the annual
vaccination campaign against rabies in dogs and cats in
the urban area of Botucatu (22° 88’ 83’ S, 48° 44’ 5” W). A
confidence interval of 95% and an estimation error of 10%
associated with the casual participation of an animal (50%
of positive responses for participation) were considered
for the determination of the sample size. In Brazil, the first
vaccine shot is administered at three months of age and
the booster dose should be given 30–45 days after the ini-
tial one, with subsequent annual revaccination [11].
The present study involved 576 dogs older than three
months of age, which had never been vaccinated against
rabies, regardless of breed, age or sex and randomly se-
lected for blood collection. Samples were collected at five
moments of the study period. The first blood sample was
taken during the annual vaccination campaign againstl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Experimental design of the present study.
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the cephalic vein, saphenous or jugular (with a 3-mL syr-
inge and 30 × 7 mm needle) and placed in sterile test
tubes without anticoagulant. The days of blood collection
were labeled as follows: 0 (on the day of the first vaccine
dose), 1 [30 days after first vaccination (dafv) and the same
day as the second dose of vaccine], 2 (60 dafv), 3 (180
dafv) and 4 (360 dafv).
Thirty days after the first immunization (moment 1),
dogs received the booster dose with the same type of
vaccine (Figure 1). This study was characterized as longi-
tudinal and was composed of a single experimental
group, since a control group was not allowed (unvaccin-
ated animals in a mass campaign against rabies) accord-
ing to a city's law [12]. The vaccine employed in this
study was from lot number 187/08, each 2-mL dose was
subcutaneously injected (between scapulae), the batch
was manufactured on December 16, 2008, sent to Lanagro
on December 27, 2008 and released on March 6, 2008,
titration (National Institutes of Health method) was
3.06 IU/dose. Determination of serum neutralizing anti-
bodies to rabies virus was performed at the Laboratory of
Zoonoses and Vector-Borne Diseases of the Center for
Zoonosis Control of São Paulo by means of the rapid
fluorescent focus inhibition test (RFFIT) according to
Smith et al. [13], modified by Zalan et al. [14]. A protect-
ive titer was considered when neutralizing antibodies ≥
0.5 IU/mL [15]. In order to quantify the occurrence of
protective titers, the frequency distribution of responsesTable 1 Percentage of dogs with protective antibody titers ag
vaccine at four different periods, 2014
Titer
30 dafv 60 dafv









Protected 460 89.1 478 99.8
Not protected 56 10.9 1 0.2
Total 516 100 479 100and the percentage of vaccine response among sampling
periods were considered in relation to the initial mo-
ment, taking into account the loss of dogs during the
study (207 died).
Of the 576 studied animals, none showed any evidence
of protective antibody titers (<0.5 IU/mL) at moment 0.
One of the biggest obstacles of this research was the loss
of animals, since numerous dogs run away during the
study period or were killed by cars. According to reports
from the owners 207 dogs (35.9%) were lost.
Table 1 shows that 89.1% of the animals reached pro-
tective titers, indicating a growth of 12% due to the sec-
ond vaccine shot. From the second moment on, the
animals demonstrated a reduction in antibody titers.
After 360 dafv, only 54.7% of the dogs had protective ti-
ters. The ratios between the number of protected ani-
mals and those unprotected during the study were: 8.2:1
at the first moment, 478:1 at the second moment, 7.7:1
at the third moment and 1.2:1 at the fourth moment
(Table 1). Of the 576 dogs, 207 either died or run away.
Then, of the remaining 369 animals, none was protected
at the first moment, 27 (7.3% out of 369) were protected
at moments 1 and 2, 109 (29.5%) had protective titers in
the period between moments 1 and 3, 13 dogs (3.5%)
were protected only in moment 2, 17 (4.6%) in moments
2 and 3, 12 dogs (3.3%) had protective titers between
moments 2 and 4, one dog (0.3%) did not reach any pro-
tective level and 190 (51.5%) animals maintained pro-
tective titers during the 360 days.ainst rabies vaccinated with Fuenzalida-Palácios modified
180 dafv 360 dafv











338 88.5 202 54.7
44 11.5 167 45.3
382 100 369 100
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nated against rabies has been previously reported [16-19].
Similarly, the immune response of dogs vaccinated only
one time has already been evaluated and the results
showed a rapid drop of antibody titers, which suggests
that several animals are unprotected among vaccination
campaigns [10,20].
According to the Pasteur Institute [21], titers below
0.5 IU/mL do not protect animals against rabies. In the
present study, 45.3% of the dogs that received the first dose
followed by booster shot (30 dafv) did not present protect-
ive antibody concentrations after 12 months (Table 1),
which is not an expected result.
The World Health Organization (WHO) recommends
that 75% of the canine population of any country should
be vaccinated. However, the program for rabies control of
São Paulo state recommends a coverage of at least 80%
[11,22]. In the 2009 vaccination campaign in Botucatu city,
SP, the immunization coverage reached 81.36% of the ani-
mals. However, only 54.7% of the first vaccinated animals
showed protective levels one year after the initial dose
(Table 1).
In a study by Hirayama et al. [23] the same vaccine
used in the current work was administered to animals
without the booster doses. The authors found that the
titers declined 120 dafv, therefore 40% of the animals
did not have protective titers. In the present study, how-
ever, the drop of serum antibody titers (<0.5 IU/mL) in
dogs occurred after the third time (180 dafv) (Table 1).
In Brazil, vaccination campaigns against rabies are annual
and booster doses are recommended 30 to 45 days after the
first shot. However, the booster dose is voluntary and the
owner must take the animal to a health surveillance center
to receive it [7]. In the present research, we found that after
the third dose (180 dafv), 88.5% of the dogs remained pro-
tected against rabies virus (titer ≥ 0.5 IU/mL) (Table 1). This
value was a greater value than that found by Shimazaki
et al. [24], who evaluated the immune response in un-
vaccinated dogs and in animals vaccinated with a single
dose of Fuenzalida- Palácios modified vaccine.
Soares et al. [8] observed that 120 days after vaccin-
ation, only 58% of the studied canine population, which
received the vaccine for the first time, had antibody
serum titers considered protective. They also reported
that 30 days after the first shot, 91.2% of the dogs had
protective titers whereas Almeida et al. [9] described
only 27.4%. In the current study, at the fourth moment
(360 dafv), 54.7% of the dogs had protective antibody ti-
ters, a higher value than that found by Soares et al. [8]
who obtained 35.3% and by Almeida et al. [9] who
found 18.3% in animals that did not receive the booster
dose. When they discussed the determinants for the de-
cline in antibody concentration after vaccination, it was
hypothesized that the nutritional status, health status,and genetic ancestry may influence the immune re-
sponse, the antibody induction and the maintenance of
antibody titers in dogs [25].
Conclusion
Our present findings showed that after the first vaccin-
ation, 51.5% of the dogs had protective titers during the
five study periods. After a year of this first shot, only
54.7% of the animals maintained protective antibody levels
against rabies. Therefore, in order to improve protective
titers against rabies for 12 months, we suggest a third dose
of vaccine at 180 days after the first one.
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